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Abstract Tau proteins are the basic components of filaments 
that accumulate within neurons during neurofibrillary degenera- 
tion, a degenerating process with disease-specific phenotypes. 
This specificity is likely to be sustained by both phosphorylation 
state and isoform content of tau aggregates that form neuronal 
inclusions. In the present study, characterization of tau isoforms 
involved in neurofibrillary degeneration in Alzbeimer's disease, 
Pick's disease, corticobasal degeneration and progressive supra- 
nuclear palsy was performed. Both analyses by immunoblotting 
using specific tau antibodies and cell transfection by tau isoform 
cDNAs allowed us to demonstrate the aggregation of (1) the six 
hyperpbosphorylated tau isoforms in Alzheimer's disease, (2) tau 
isoforms without exon 10-encoding sequence in Pick's disease 
and (3) hyperphosphorylated exon 10-tau isoforms in corticoba- 
sal degeneration and progressive supranuclear palsy. Thus, 
neurofibrillary degeneration phenotypes are likely to be related 
to the phosphorylation of different combinations of tau isoforms 
(with and/or without exon 10-encoding sequence) in subpopula- 
tions of neurons. 
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1. Introduction 
Hyperphosphorylated microtubule-associated tau proteins 
are the main components of the aggregated filaments found 
in neurofibrillary tangles (NFT) in Alzheimer's disease (AD) 
and are referred to as paired helical filaments (PHF) [1-3]. 
Similar tau immunoreactivity s observed in NFT in other 
neurodegenerative disorders including corticobasal degenera- 
tion (CBD) and progressive supranuclear palsy (PSP) (for re- 
view [4]). In CBD and PSP, tau aggregation results in the 
formation of non-PHF filaments. Other neuronal inclusions 
such as Pick bodies in Pick's disease (PiD) are also tau-im- 
munoreactive [5]. 
The human tau gene is located over 100 kb on the long arm 
of chromosome 17 at band position 17q21 and contains 16 
exons [4,6]. In the brain, alternative splicing of three exons 
(exons 2, 3 and 10) allows six combinations (2 -3 -10- ;  
2+3-10- ;  2+3+10-; 2 -3 -10+;  2+3-10+; 2+3+10+) 
[7,8]. Thus, tau proteins constitute a family of six isoforms 
which range from 352 to 441 amino acids. They differ from 
each other by either the presence of three (10-) or four re- 
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peat-regions (10+) in the carboxy-terminal part of the mole- 
cule and one (2+) or two (2+3+) inserts (29 or 58 amino 
acids) in the amino-terminal part [7,8]. Furthermore, the six 
tau isoforms may not be equally expressed in neurons. For 
instance, tau mRNAs containing exon 10 (El0+) are not de- 
tected in granular cells of the dentate gyrus suggesting that 
these particular tau isoforms are weakly expressed or lacking 
in these neurons [7]. Thus, tau isoforms may be differentially 
distributed in neuronal subpopulations and/or cell compart- 
ments. 
In AD, the six tau isoforms are hyperphosphorylated and 
aggregate into PHF. By immunoblotting, PHF-Tau are char- 
acterized by a tau triplet Tau 55, 64, 69 and a minor electro- 
phoretic variant at 74 kDa [9]. In PiD, aggregated tau pro- 
teins are made of a major tau doublet Tau 55, 64 and a minor 
variant at 69 kDa [5,10], whereas in PSP, CBD and in some 
cases with fronto-temporal dementia with parkinsonism 
linked to chromosome 17 (FTDP-17), another tau doublet 
Tau 64, 69 with a minor variant at 74 kDa, characterizes 
neuronal and glial filaments [5,11,12]. Recent data indicate 
that the tau electrophoretic profiles observed in neurodegener- 
ative disorders may be related to specific tau isoforms in par- 
ticular subsets of neurons [13]. 
We investigated this hypothesis (1) by transfection of COS 
cells, using different combinations of tau isoform cDNAs, and 
followed by a treatment with okadaic acid (OA), a phospha- 
tase 1 and 2A inhibitor, and (2) by using monoclonal and 
polyclonal antibodies to compare tau immunoreactivity in 
cell extracts and brain homogenates from AD, CBD, PSP 
and PiD. 
2. Materials and methods 
2.1. Patients 
All of the patients (AD, PSP, CBD, PiD) used in the present study 
have been described in previous works [5,14~16]. PiD cases howing 
only Pick bodies were used in the present study. 
2.2. Antibodies 
Phosphorylation-dependent monoclonal antibodies (12E8, AD2, 
and AT100) were used to characterize tau proteins. 12E8 recognizes 
phosphorylated Ser-262 [17]. AD2 is directed against phosphorylated 
Ser-396 and 404 [15]. AT100 binds to a conformational epitope in- 
cluding phosphorylated Thr-212 and Ser-214 [18]. 
Polyclonal antibodies, E2, E3 and El0 respectively, raised against 
tau sequences ncoded by spliced exons (2, 3 and 10) were also used 
[19]. 
2.3. Cell culture and transJ~'ction 
COS-7 cells were grown in 25 cm 2 flasks in Dulbecco's modified 
Eagle medium (Life Technologies) with 10% fetal calf serum (Boehr- 
inger Mannheim) in a 5% CO2 incubator at 37°C. cDNA of the six 
human tau isoforms were cloned in pSG5 vector (Stratagene). They 
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are a kind gift from Dr. Michel Goedert (Cambridge, UK). Tau 
cDNAs were transiently transfected in COS cells using the DEAE- 
dextran method. Following 42 h transfection, cells were treated or not 
by OA (Sigma), a phosphatase 1 and 2A inhibitor, for 6 h in serum- 
free medium [20]. Cells were then harvested in Tris-EDTA solution at 
4°C and centrifuged. Cell pellets were homogenized in Laemmli sam- 
ple buffer and boiled for 10 min. 
2.4. lmmunoblott ing 
Electrophoresis and immunoblotting were performed as previously 
described [15]. Briefly, samples were loaded onto 10% SDS-PAGE 
(Pharmacia Biotech). After transfer and blocking, membranes were 
incubated with the primary antibody 90 rain at room temperature. 
Horseradish peroxidase-conjugated antibody (Sigma) was used as sec- 
ondary antibody and reaction product was detected using the Amer- 
sham ECL Western blotting system. 
3. Results 
Immunochemical characterization of tau variants in neuro- 
degenerative disorders using AD2 was consistent with that 
performed in previous studies [1 5,9-11,14,16]. A major tau 
triplet made of Tau 55, 64 and 69 and a minor variant at 74 
kDa were found in AD (Fig. I A, Fig. 3A). Only the two 
major variants of higher MW, Tau 64 and 69, were found 
in CBD and PSP (Fig. 1B, Fig. 3A). The 74 kDa electropho- 
retic variant was poorly detected. In AD, all electrophoretic 
variants were immunoreactive with antibodies AD2, AT100 
and 12E8 (Fig. 1A, Fig. 3A,B). In CBD and PSP, similar 
tau immunoreactivity was found indicating that the same 
tau epitopes as in AD are hyperphosphorylated (Fig. 1B, 
Fig. 3A,B). In PiD, Tau 55 and 64, and a minor 69 kDa 
electrophoretic variant were previously described [5,10]. 
They are labeled by AD2 and AT100 whereas 12E8 did not 
bind to the tau variants suggesting that Tau 55 and 64 are not 
phosphorylated at Ser-262 (Fig. 3B). In the present study, all 
data were similar in CBD and PSP. Thus, we will use in the 
next paragraphs the abbreviation CBD/PSP for both disorders 
to facilitate the description. 
By immunoblotting, it was previously shown that in AD, all 
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Fig, 1. lmmunoblotting of tau proteins using antibodies raised 
against exon-encoding sequences (E2, E3 and El0) and phosphoryl- 
ation-dependent monoclonal antibodies AD2 and AT100. A: In 
AD, Tau 74 and 69 are labeled by all antibodies E2, E3 and El0. 
Tau 64 is labeled by both E2 and El0. Tau 55 is never labeled. All 
phosphorylation-dependent antibodies label the tau triplet Tau 55, 
64 and 69 with the minor 74 kDa variant. B: In CBD, E2 labels 
Tau 69 and 74. E3 only labels Tau 74. The tau doublet Tau 64 and 
69 and the minor 74 kDa variant are labeled by El0. All phospho- 
rylation-dependent antibodies label the tau doublet Tau 64 and 69 
with the minor 74 kDa variant in CBD. In all disorders, minor tau 
species are also labeled by the different antibodies and correspond 
to non-phosphorylateed tau proteins as described in [9,10,13]. Mo- 
lecular weights (55-74 kDa) are indicated on the left side of the fig- 
ure (arrowheads). Black dots at the right part of each immunoblots 
indicate the position of labeled hyperphosphorylated auvariants. 
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Fig. 2. lmmunoblotting of tau proteins in transfected COS cells us- 
ing the tau polyclonal antibody MI9G (A) and the phosphoryla- 
tion-dependent monoclonal antibody AD2 (B). A: Each tau isoform 
in OA treated (+) and non OA treated ( - )  transfected COS cells is 
characterized by different electrophoretic variants that are likely to 
reflect different degrees of tau phosphorylation. However, there is a 
notable shift of MW between tau isoforms from non OA treated 
(-)  and OA treated (+) transfected COS cells. This shift is induced 
by tau hyperphosphorylation. B: The phosphorylation-dependent 
antibody AD2 only labels the upper hyperphosphorylated au var- 
iants in OA treated transfected COS cells (+). In some cases 
(2 -3 -10-  and 2+3-10+), lower hyperphosphorylated auvariants 
are also detected. 
six isoforms are phosphorylated to obtain the major tau trip- 
let and the 74 kDa variant [9] (Fig. 1A) whereas in PiD, Tau 
55, 64 and the minor 69 kDa variant are made of tau isoforms 
without the exon 10 translated sequence since they are not 
labeled by antibody El0 [13]. Conversely, antibody El0 
strongly labeled Tau 64 and 69 in AD and CBD/PSP and to 
a lesser extent the 74 kDa variant (Fig. 1). Further investiga- 
tion using E2 and E3 antibodies uggested that tau electro- 
phoretic variants in CBD/PSP are only made of tau isoforms 
with exon 10 translated sequence. E2 labeled both Tau 69 and 
74 whereas E3 only labeled Tau 74 (Fig. 1B). Other lower 
MW peptides were also detected. They correspond to non- 
phosphorylated tau proteins as demonstrated, in AD, by 
two-dimensional electrophoresis analysis [9]. 
To confirm at the molecular level these immunochemical 
data, we performed cell transfections with different tau iso- 
form cDNAs (Fig. 2). We used OA, a phosphatase 1 and 2A 
inhibitor, to mimic tau hyperphosphorylation found in neuro- 
degenerative disorders [20]. In OA treated transfected cells, 
tau isoforms displayed after SDS-PAGE a shift in MW indi- 
cating a hyperphosphorylation (Fig. 2A). This was confirmed 
using the phosphorylation-dependent tau antibody AD2 
which only labels tau isoforms of OA treated cells (Fig. 2B). 
In COS cells, co-transfection of the six tau isoform cDNAs 
and cell treatment by OA led to the formation of large 
amounts of all electrophoretic variants, Tau 55, 64, 69 and 
74, that were immunoreactive for all phosphorylation-depend- 
ent antibodies (Fig. 3C,D). In AD, Tau 74 is poorly detectable 
(Fig. 3A,B). Thus, this electrophoretic profile did not reflect 
quantitatively the one found in AD since tau isoforms that 
aggregate in AD brain are not expressed in equal quantities. 
Different amounts of tau isoforms were tested in our trans- 
fection experiments and the electrophoretic profile the most 
comparable to the one found in AD was observed with the 
following combination: 35% (2 -3 -10-  tau isoform), 15% 
(2+3-10- ) ,  15% (2 -3 -10+) ,  15% (2+3+10-),  15% 
(2+3-10+) and 5% (2+3+10+) (data not shown). In other 
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Fig. 3. Comparison of tau immunoreactivity from brain homoge- 
nates (A, B) and OA treated transfected COS cells (C, D) by immu- 
noblotting using phosphorylation-dependent mo oclonal antibodies 
AD2 (A, C) and 12E8 (B, D). A: AD2 labels the tan triplet Tau 
55, 64 and 69 with the minor 74 kDa electrophoretic variant in 
AD, the tau doublet Tau 55 and 64 with the minor 69 kDa variant 
in PiD and the tau doublet Tau 64 and 69 with the minor 74 kDa 
variant in CBD. B: Similar immunoreactivity is found with 12E8 
with the exception of PiD where Tau 55 and 64 are not labeled. 
For both antibodies, it should be noted that Tau 64 in PiD corre- 
sponds to the upper part (65 kDa) of the AD Tau 64 variant, 
whereas Tau 64 in CBD corresponds to its lower part (63 kDa). 
Similar observations are available for Tau 69. These data are consis- 
tent with the electrophoretic profile of tau isoforms observed in OA 
treated transfected COS cells. Using OA treated transfected COS 
cells, similar data are obtained for both antibodies AD2 (C) and 
12E8 (D). The six hyperphosphorylated au isoforms (6) run on 
SDS-PAGE as four variants at 55, 64, 69 and 74 kDa. Hyperphos- 
phorylated El0- tau isoforms (10-) run at 55, 65 and 70 kDa 
whereas hyperphosphorylated El0+ tau isoforms (10+) run at 63, 
68 and 74 kDa. These data are consistent with the results obtained 
in PiD and CBD/PSP. Molecular weights (55 and 74 kDa) are indi- 
cated on the left part of each immunoblots (arrowheads). Black 
dots indicate the position of labeled hyperphosphorylated tau var- 
iants either Tau 55, 64 and 69 in PiD or Tau 64, 69 and 74 in 
CBD. 
transfection studies using specifically E l0 -  or El0+ tau iso- 
form cDNAs to mimic PiD and CBD/PSP pathology respec- 
tively, the following combination was used (45% (2 -3 - ) ,  45% 
(2+3-) and 10% (2+3+)). Triple transfection of E l0 -  tau 
isoform cDNAs in COS cells led to the formation, after OA 
treatment, of the characteristic electrophoretic tau profile 
found in PiD showing AD2 immunoreactivity (Fig. 3C). How- 
ever, hyperphosphorylated E l0 -  tau isoforms (Tau 55 and 64 
and the minor variant at 69 kDa) obtained in transfected COS 
cells, were also 12E8-immunoreactive (Fig. 3D). This is a 
striking difference with PiD where the hyperphosphorylated 
tau variants are not 12E8-immunoreactive (Fig. 3B). 
Triple transfection of El0+ tau isoform cDNAs (45% 
(2 -3 - ) ,  45% (2+3-) and 10% (2+3+)) in COS followed by 
OA cell treatment led to the formation of tau variants exhib- 
iting the same electrophoretic tau profile as in CBD/PSP, la- 
beled by all phosphorylation-dependent mo oclonal antibod- 
ies: Tau 64 and 69 and a minor tau variant at 74 kDa (Fig. 
3C,D). Thus, the tau electrophoretic profile observed in CBD 
resulted from the hyperphosphorylation of El0+ tau isoforms 
(Fig. 1B, Fig. 3C,D). 
For all antibodies, it should be noted that Tau 64 
(2+3-10- )  in PiD corresponds to the upper part of the 
Tau 64 variant (mixture of 2+3-10-  and 2 -3 -10+)  in AD 
whereas Tau 64 (2-3-10+)  in CBD/PSP corresponds to its 
lower part (Fig. 3C,D). Similar observations are available for 
Tau 69. These data are consistent with the electrophoretic 
profile of tau isoforms observed in OA treated transfected 
COS cells (Fig. 2) and further support our findings. 
4. Discussion 
The present study demonstrates at the molecular level that 
hyperphosphorylated auisoforms with exon 10-encoding se- 
quence exhibit the same electrophoretic profiles as those 
found in CBD/PSP. It also confirms that all six hyperphos- 
phorylated tau proteins aggregate in AD whereas only tau 
isoforms lacking exon 10 translated sequence are hyperphos- 
phorylated in PiD. Thus, the tau electrophoretic profiles en- 
countered in neurodegenerative disorders may be obtained in 
cell models using specific tau isoforms (with or without exon 
l0 translated sequence) and OA cell treatment. However, dif- 
ferential tau phosphorylation (i.e. Ser-262 phosphorylation in 
PiD) was not reproduced suggesting that not only tau iso- 
forms but also particular kinases are involved in the patho- 
logical process. 
In AD, all hyperphosphorylated au isoforms (E l0 -  and 
El0+) aggregate into PHF and are biochemically character- 
ized by a tau triplet that is labeled by all phosphorylation- 
dependent tau monoclonal ntibodies (for review [4]). All neu- 
rodegenerative disorders with PHF-like filaments including 
Guamanian amyotrophic lateral sclerosis/parkinsonism de-
mentia complex and postencephalitic parkinsonism are also 
characterized by this tau triplet [14,16]. Tau cDNA from 
each of the six tau isoforms was previously transfected into 
COS cells leading to the formation of different peptides that 
are likely to be related to different degrees of phosphorylation 
[22]. After transfection of tau isoform cDNAs, a cell treat- 
ment by OA was performed and allowed us to induce the 
highest degrees of phosphorylation [20,23]. Using the method 
with all six tau isoforms, an electrophoretic profile similar to 
that found in AD was observed. These data are comparable to
those describing tau phosphorylation by GSK3[5 [24]. Follow- 
ing this approach, the different au electrophoretic profiles 
found in CBD and PiD may be explained. In PiD, Pick bodies 
consist of random coiled filaments made of aggregated E I0 -  
tau isoforms that are found in these characteristic neuronal 
populations [13,19]. For instance, granular cells of the dentate 
gyrus are one of the cell types that exhibit Pick bodies in PiD: 
they do not express El0+ isoforms [7]. Our transfection stud- 
ies indicate that hyperphosphorylated E l0 -  isoforms lead to 
the same electrophoretic profile as that found in PiD (Tau 55 
and 64). Thus, this is the molecular demonstration that E10-  
tau isoforms are found in Pick bodies. Conversely, in CBD 
and likely in PSP, only El0+ tau isoforms aggregate into 
straight filaments. The characteristic tau doublet Tau 64 and 
69 are obtained after transfection of El0+ tau isoforms and 
their hyperphosphorylation. It was reported that exon 3 trans- 
lated sequence was not found in CBD [25]. This controversial 
finding may be explained by the very low amount of the 
2+3+10+ isoform found phosphorylated in CBD at 74 kDa. 
Thus, El0+ tau isoforms are likely to aggregate in subsets of 
neurons that are degenerating in PSP/CBD. It should also be 
noted that particular tau gene polymorphisms in PSP may 
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modify alternative splicing and lead to an increase in El0+ 
tau isoforms formation [26]. Similarly, in FTDP-17, point 
mutations in introns close to exon 10 may also increase levels 
of El0+ tau isoforms further leading to their aggregation 
[27,28]. A point mutation in exon 10 was also reported in 
one family with FTDP-17. It is located in the microtubule 
binding domain and is likely to induce important conforma- 
tional changes leading to a lack of binding to microtubules. In
this family, El0+ tau proteins aggregate into filaments and 
are mainly characterized by the tau doublet Tau 64 and 69 
[27]. These data suggest hat tau isoforms that do not bind to 
microtubules may aggregate into filaments. Thus, our data are 
consistent with recent genetic analyses uggesting that partic- 
ular tau isoforms may aggregate in subsets of neurons. 
However, it should be noted that differences in tau phos- 
phorylation were observed between pathology and transfec- 
tion studies. The 12E8 immunoreactivity was not found in 
PiD in two studies [13,21] whereas it was present in a neuro- 
pathological analysis in one case [29] and also in the present 
study, after transfection of E l0 -  tau isoforms and cell treat- 
ment by OA. Conversely, AD2 and AT100 immunoreactivities 
were obtained in our cell model suggesting that the sequential 
phosphorylation GSK3[3 and pKA responsible for ATI00 
epitope formation [18] occurs in COS cells. Such cascades of 
kinases were already suggested in COS cells [23]. Thus, trans- 
duction signals involved in kinases activation/phosphatases 
inhibition are much more complex than a single hyperphos- 
phorylation process. 
In conclusion, degeneration of neurons leads to the aggre- 
gation and hyperphosphorylation of their constitutive tau iso- 
forms. Thus, the biochemical signatures (Tau 55 and 64, Tau 
64 and 69, Tau 55, 64 and 69) found in neurodegenerative 
disorders are related to the presence of both different combi- 
nations of tau isoforms (E l0 -  and/or El0+) and particular 
kinases in subpopulations of neurons. 
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